Clinical Trial Update: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial assessing talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy for HER2-negative breast cancer has completed, sp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• T-VEC (talimogene laherparepvec)

Snippet

Sponsor: University of California, San Francisco | Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 | Status: COMPLETED